CCR5Δ32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Δ32 homozygous individual

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Oh, Djin Ye ^a,d   Jessen, Heiko ^b   Kücherer, Claudia ^c   Neumann, Konrad ^a   Oh, Nari ^b   Poggensee, Gabriele ^c   Bartmeyer, Barbara ^c   Jessen, Arne ^b   Pruss, Axel ^a   Schumann, Ralf R ^a   Hamouda, Osamah ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Gemeinschaftspraxis Jessen Jessen Stein   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE;

ADULT; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE DELETION; GENOTYPE; GERMANY; HETEROZYGOSITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROCTITIS; SEROCONVERSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 50249130217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002747     Document Type: Article

References (46)

1. Arenzana-Scisdedos F. Parmemier M (2006) Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol 18: 387-403.
2. Lederman MM, Penn-Nicholson A, Cho M, Mosier D (2006) Biology of CCR5 and its role in HIV infeation and treatment. Jama 296: 815-826.
3. Huang Y, Paxton WA, Wotinsky SM, Neumann AU, Zhang I, et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2: 1240-1243.
4. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
5. Samson M, Libert F. Doramz BJ, Rucker J Liesnard C. et al. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-725.
6. Marmor M, Sheppard HW, Donnell D, Bozeman S. Celum C, et al. (2001) Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 27: 472-481.
7. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-1862.
8. Hendel H, Henon N, Lebuanec H, Lachgar A, Poncelet H, et al. (1998) Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol 19: 381-386.
9. Misrahi M, Teglas JP, N'Go N, Burgard M, Mayaux MJ, et al. (1998) CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. Jama 279: 277-280.
10. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, Goedert JJ, De Rossi A, et al. (2003) Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. Aids 17: 1631-1638.
11. Mullherin SA, O'Brien TR, Ioannidis.JP, Goedert JJ, Buchbinder SP, et al. (2003) Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. Aids 17: 377-387.
12. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, et al. (1998) Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279: 389-393.
13. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, et al. (1999) HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283: 1748 1752.
14. Trachtenberg E, Korber B. Sollars C. Kepler TB, Hraber PT, et al. (2003) Advaniage of rare HLA suptype in HIV diseases progression. Nat Med 9: 928-935.
15. Martin MP, Qi Y, Gan X, Yamada E, Martin JN, et al. (2007) Innate partnership of HLA-B and KIR3DLI subtypes against HIV-1. Nat Genet 39: 733-740.
16. O'Brien SJ, Nelson GW (2001) Human genes that limit AIDS. Nat Genet 36: 565-574.
17. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, et al. (1997) Homozygous delta 32 deletion ofthe CCR-5 chemokine receptor gene in an HIV-1-infected patient. Aids 11: F67 71.
18. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, et al. (1997) HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 3: 252-253.
19. Gorry PR, Zhang C, Wu S, Kunstman K, Trachtenberg E, et al. (2002) Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet 359: 1832-1834.
20. Gray L, Churchill MJ, Keane N, Sterjovski J, Ellett AM, et al. (2006) Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous lot the CCR5delta32 allele. J Virol 80: 3684-3691.
21. Heiken H, Becker S, Bastisch I, Schmidt RE (1999) HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32. Aids 13: 529-530.
22. Kuipers H, Workman C, Dyer W, Geczy A, Sullivan J, et al. (1999) An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3'A allele. Aids 13: 433-434.
23. O'Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, et al. (1997) HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 349: 1219.
24. Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M, et al. (2002) HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition ofsyncytium-inducing virus at scroconversion J Acquir Immune Defic Syndr 29: 307-313.
25. Theodorou I, Meyer L, Magierowska M, Kadama C, Rouzioux C (1997) HIV-1 infection in an individual homozygous for CCR5 delta 32. Scroco Study Group. Lancet 349: 1219-1220.
26. Iversen AK, Christainsen CB, Attermann J, Eugen-Olsen J, Schulman S, et al. (2003) Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency vints infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus. J Infect Dis 187: 215-225.
27. Bhaskaran K, Brettle R, Porter K, Walker AS (2004) Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. Aids 18: 673-681.
28. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, et al. (2005) Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from scroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 40: 505-511.
29. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, et al. (2006) The impact of trainsmitted drug resistance on the natural history of HIV infection and response to first-line therapy. Aids 20: 21-28.
30. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, et al. (2001) Frequency of genotypic and phenotypic drug-resistant HIV-1 amonq therapy-naive patients of the German Scroconverter Study. J Acquir Immune Defic Syndr 26: 266-273.
31. Neiler S, Somogyi S, Schlote F, Berg T, Poggensee G, et al. (2006) Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment. Aids 20: 2231-2233.
32. Poggensee G, Kucherer C, Werning J, Somogyi S, Bienick B, et al. (2007) Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Scroconverter Study. HIV Med 8: 511-519. .
33. Oh DY, Taube S, Hamouda O, Kuccherer C, Hattermann K, Neumann K, Schumann RR (2008) A Frequent Functional Toll-like Receptor 8 Variant is Associated with Restriction of HIV Disease Progression. Journal of infections Diseases, In Press.
34. Kristiansen TB. Knudsen TB, Ohlendorff S. Eugen-Olsen J. (2001) A new multiplex PCR strategy for the simultaneous determination of four genetic polymorphisms affecting HIV-1 disease progression. J Immunol Methods 252: 147-151.
35. Kaur G, Singh P, Rapthap CC, Kumar N, Vajpayee M, et al. (2007) Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians. Hum Immunol 68: 454-161.
36. Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q Bui J. et al. (2006) Genetic association of the antiviral ristriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 80: 2163-2171
37. Patke DS, Langan SJ, Carruth LM. Keating SM, Sabundayo BP, et al. (2002) Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point. J Infect Dis 186: 1177-1180.
38. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB (1997) Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 16: 100-103.
39. Hummel M. Bara C. Hirt S, Haverich A, Hetzer R (2007) Prevalence of CCR5Delta32 polymorphism in long-iterm survivors of heart transplantation. Transpl Immunol 17: 223-226.
40. Philpott S, Burger H, Charbonneau T, Grimson R, Vermund SH, et al. (1999) CCR5 genotype and resistance to vertical transmission of HIV-1. J Acquir Immune Defic Syndr 21: 189-193.
41. Pasi KJ, Sabin CA, Jenkins PV, Devereux HL, Ononye G, et al. (2000) The effects or the 32-bp CCR-5 deletion on HIV, transmission and HIV disease progression in individuals with haemophilia. Br J Haematol 111: 136-142.
42. Michael NI, Nelson JA, KewalRamani VN, Chang G, O'Brien SJ, et al. (1998) Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 72: 6010-6017.
43. Weiser B, Phillpott S, Klimkait T, Burger H, Kitchen C, et al. (2008) HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. Aids 22: 469-479.
44. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, et al. (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66: 1354-1360.
45. + cell depletion and progression to AIDS. Ann Intern Med 118: 681-688.
46. Kreisberg JF, Kwa D, Schramm B, Trautner V, Connor R, et al. (2001) Cycopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J Virol 75: 8842-8847.